scholarly journals Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment

2016 ◽  
Vol 67 (6) ◽  
pp. 676-679 ◽  
Author(s):  
Brendan Saloner ◽  
Kenneth B. Stoller ◽  
Colleen L. Barry
Keyword(s):  
Addiction Treatment ◽  
Methadone Maintenance ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Medicaid Coverage ◽  
Opioid Agonist Therapy

scholarly journals Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment

Medical Care ◽  
2017 ◽  
Vol 55 (12) ◽  
pp. 985-990 ◽  
Author(s):  
Marcus A. Bachhuber ◽  
Pooja K. Mehta ◽  
Laura J. Faherty ◽  
Brendan Saloner
Keyword(s):  
Pregnant Women ◽  
Methadone Maintenance ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Medicaid Coverage ◽  
Opioid Agonist Therapy

scholarly journals Optimizing Hepatitis C Virus (HCV) Treatment in a US Colocated HCV/Opioid Agonist Therapy Program

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Jackie Habchi ◽  
Aurielle M Thomas ◽  
Sophie Sprecht-Walsh ◽  
Elenita Arias ◽  
Jeffrey Bratberg ◽  
...  
Keyword(s):  
United States ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Methadone Maintenance ◽  
The United States ◽  
Opioid Use ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy

Abstract Background A minority of patients with opioid use disorder are treated for hepatitis C virus infection (HCV). While colocated HCV and opioid agonist therapy (OAT) along with harm reduction can facilitate prevention and cascade to cure, there are few real-world examples of such embedded care models in the United States in the direct-acting antiviral (DAA) era. Methods We conducted a retrospective chart review to determine sustained virologic response (SVR) and reinfection rates during the first 5-year period of DAA availability among individuals tested and treated on-site at Rhode Island’s only nonprofit methadone maintenance program. Results Of 275 who initiated DAAs, the mean age (range) was 43 (22–71) years, 34.5% were female, 57.5% had genotype 1a, 23.3% had cirrhosis, and 92% were Medicaid recipients. SVR was 85.0% (232/273), while modified intent-to-treat SVR was 93.2% (232/249); 17 patients did not achieve SVR, 2 awaited SVR 12 weeks post-end-of-treatment, and 24 were lost to follow-up. Thirty reinfections were identified over 375.5 person-years of follow-up (rate, 7.99/100 person-years). The median time to first reinfection (interquartile range) was 128 (85.25–202.5) days. Before July 1, 2018, 72 patients accessed DAAs over 3.7 years; after Medicaid DAA restrictions were lifted, 109 patients accessed DAAs over 1.3 years. The Prior Authorization (PA) process requires many steps, differing across 11 RI insurers, taking 45–120 minutes per patient. Conclusions DAA treatment was effective among a marginalized population in an urban colocated OAT/HCV program. Removing DAA restrictions facilitates treatment initiation. The PA process remains a modifiable barrier to expanding capacity in the United States.

scholarly journals Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions

2019 ◽  
Vol 55 (2) ◽  
pp. 232-238
Author(s):  
Kayla N. Tormohlen ◽  
Noa Krawczyk ◽  
Kenneth A. Feder ◽  
Kira E. Riehm ◽  
Rosa M. Crum ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Treatment ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Medicaid Coverage ◽  
Opioid Agonist Therapy

scholarly journals Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial

2022 ◽  
Vol 12 ◽  
Author(s):  
Christopher S. Stauffer ◽  
Salem Samson ◽  
Alex Hickok ◽  
William F. Hoffman ◽  
Steven L. Batki
Keyword(s):  
Addiction Treatment ◽  
Controlled Trial ◽  
Significant Risk ◽  
Controlled Clinical Trial ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Treatment ◽  
Stimulant Use ◽  
Opioid Agonist Therapy ◽  
Male Veterans

The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current treatment options are limited. Oxytocin administration has shown promise in reducing addiction-related behavior and enhancing salience to social cues. We conducted a randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin administered twice daily for 6 weeks to male Veterans with stimulant use disorder who were also receiving opioid agonist therapy and counseling (n = 42). There was no significant effect of oxytocin on stimulant use, stimulant craving, or therapeutic alliance over 6 weeks. However, participants receiving oxytocin (vs. placebo) attended significantly more daily opioid agonist therapy dispensing visits. This replicated previous work suggesting that oxytocin may enhance treatment engagement among individuals with stimulant and opioid use disorders, which would address a significant barrier to effective care.

950 Association between capacity for maternal opioid agonist therapy treatment and neonatal abstinence syndrome

2021 ◽  
Vol 224 (2) ◽  
pp. S589-S590
Author(s):  
Bronwyn S. Bedrick ◽  
Carly O'Donnell ◽  
Christine Marx ◽  
Hayley Friedman ◽  
Ebony B. Carter ◽  
...  
Keyword(s):  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Therapy Treatment

scholarly journals The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting

2017 ◽  
Vol 176 ◽  
pp. 133-138 ◽  
Author(s):  
Joseph K. Eibl ◽  
Graham Gauthier ◽  
David Pellegrini ◽  
Jeffery Daiter ◽  
Michael Varenbut ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy
Sign in / Sign up

Export Citation Format

Share Document